Management of indolent lymphoma: where are we now and where are we going.
Indolent lymphoma comprises a unique and challenging subset of non-Hodgkin lymphoma (NHL). While definitions of indolence will vary, the most common indolent NHL subtypes include follicular lymphoma, marginal zone lymphoma, and small lymphocytic lymphoma. Patients with indolent NHL (iNHL) excluding those with rare localized presentations are often met with an incurable but highly treatable NHL. In the rituximab era, response rates are approaching 90% with rituximab plus chemotherapy and time to next treatment are beginning to be measured in years. As a result of a prolonged natural history, we are encountering a gridlock of novel regimens and agents that appropriately fill peer-reviewed journals. In this review, we tackle a spectrum of topics in the management of indolent lymphoma including the initial approach to the newly diagnosed patient, approaches to first cytotoxic chemotherapy, maintenance and consolidation techniques, as well as highlight promising treatments on the horizon in iNHL. Clinicians continue to face tough choices in the management of iNHL. Through well-thought out clinical trials and peer-reviewed vetting of data we will continue to determine how to best manage the clinical continuum that is iNHL.
Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY, 10065, United States. lunningm@mskcc.org
Matthew A
MA
Lunning
Julie M
JM
Vose
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D007167:Immunotherapy / Q000379:methods; D008228:Lymphoma, Non-Hodgkin / Q000175:diagnosis* / Q000276:immunology / Q000378:metabolism / Q000628:therapy*; D058990:Molecular Targeted Therapy / Q000379:methods; D061988:Proteasome Inhibitors / Q000627:therapeutic use; D033581:Stem Cell Transplantation / Q000379:methods
D000970:Antineoplastic Agents; D007155:Immunologic Factors; D061988:Proteasome Inhibitors